Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
BIOATLA, INC. currently has 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 9 actions are distributed among 9 distinct examiners, which means that every pending matter is being reviewed by a different person. This distribution across 9 distinct examiners suggests a wide range of examiner interactions for the company. The portfolio is also spread across 7 distinct art units, indicating that the company's pharmaceutical innovations cover a broad spectrum of technical classifications.
HOLTZMAN, KATHERINE ANN is the busiest examiner for this portfolio, with 1 pending office action. This is consistent with the other distinct examiners, each of whom also has 1 pending action. The 7 distinct art units involved suggest that the 9 pending office actions are subject to various internal policies and prior art databases. Practitioners should coordinate their efforts to ensure that the 9 distinct examiners receive consistent arguments, even as they work across 7 different art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (22%) |
| §103 only | 1 (11%) |
| §112 only | 2 (22%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 1 (11%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLTZMAN, KATHERINE ANN | 1 | 65.7% | +58.3% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| BOESEN, CHRISTIAN C | 1 | 75.9% | +21.1% |
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
| MERTZ, PREMA MARIA | 1 | 71.7% | +35.4% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694273 | CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES | HOLTZMAN, KATHERINE ANN | — |
| 18341913 | METHOD FOR PREPARING A CONDITIONALLY ACTIVE ANTIBODY OR ANTIBODY FRAGMENT | BOESEN, CHRISTIAN C | — |
| 18252542 | METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES | MERTZ, PREMA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17820913 | CONDITIONALLY ACTIVE POLYPEPTIDES | CANELLA, KAREN A | 51d overdue |
| 18002010 | CONDITIONALLY ACTIVE ANTI-CD46 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | BERHANE, SELAM | 45d overdue |
| 18694273 | CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES | HOLTZMAN, KATHERINE ANN | — |
| 18402642 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | AEDER, SEAN E | — |
| 18341913 | METHOD FOR PREPARING A CONDITIONALLY ACTIVE ANTIBODY OR ANTIBODY FRAGMENT | BOESEN, CHRISTIAN C | — |
| 18334769 | MIRAC PROTEINS | LEITH, NANCY J | — |
| 18252542 | METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES | MERTZ, PREMA MARIA | — |
| 17759195 | Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses Thereof | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1684 | 2 |
| 1642 | 1 |
| 1636 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694273 | CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES | HOLTZMAN, KATHERINE ANN | — | §101§103§112Other | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18402642 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | AEDER, SEAN E | 1642 | Other | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18341913 | METHOD FOR PREPARING A CONDITIONALLY ACTIVE ANTIBODY OR ANTIBODY FRAGMENT | BOESEN, CHRISTIAN C | 1684 | §101§102DP | Non-Final OA | — | Pending | Jun 27, 2023 |
| 18334769 | MIRAC PROTEINS | LEITH, NANCY J | 1636 | §112DP | Non-Final OA | — | Pending | Jun 14, 2023 |
| 18252542 | METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES | MERTZ, PREMA MARIA | 1674 | §103§112 | Non-Final OA | — | Pending | May 11, 2023 |
| 18002010 | CONDITIONALLY ACTIVE ANTI-CD46 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | BERHANE, SELAM | 1675 | §112 | Final Rejection | 45d overdue | Pending | Dec 15, 2022 |
| 17820913 | CONDITIONALLY ACTIVE POLYPEPTIDES | CANELLA, KAREN A | 1643 | §112DP | Non-Final OA | 51d overdue | Pending | Aug 19, 2022 |
| 17759195 | Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses Thereof | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112 | Final Rejection | — | Pending | Jul 21, 2022 |
| 17807954 | EXPRESS HUMANIZATION OF ANTIBODIES | GROSS, CHRISTOPHER M | 1684 | §103 | Final Rejection | — | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial